0
Il n'y a pas de produit dans le panier !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > BAFFR

BAFFR

Brief Information

Name:B-cell activating factor receptor
Target Synonym:BAFFR,B Cell-Activating Factor Receptor,Prolixin,BROMIX,CD268,Tumor Necrosis Factor Receptor Superfamily, Member 13C,Tumor Necrosis Factor Receptor Superfamily Member 13C,BR3,CVID4,CD268 Antigen,BAFF Receptor,B-Cell Activation Factor Receptor,BAFF-R,TNF Receptor Superfamily Member 13C,BLyS Receptor 3,B-Cell-Activating Factor Receptor,TNFRSF13C
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Phase 3 Clinical

Antibody Licensing

Project Name Project Stage Molecule Type Host Species Therapeutic Area Indications
BAFFR&CD3 BsAb - 01 PCC Hematological Malignancy,AutoImmunity Blood tumor,Autoimmune disease

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

BAR-HP2H6-Cell-based assay
 BAFFR FACS

5e5 of anti-BAFFR CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human BAFFR Protein, His Tag (Cat. No. BAR-HP2H6) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

BAR-H5258-SPR
 BAFFR SPR

Immobilized Human BAFF Protein, Fc Tag (Cat. No. BAF-H5261) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFFR Protein, Llama IgG2b Fc Tag (Cat. No. BAR-H5258) with an affinity constant of 44.5 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BAR-H5257-SPR
 BAFFR SPR

Immobilized Biotinylated Human BAFF, Avitag,Fc Tag (active trimer) (MALS verified) (Cat. No. BAF-H82F3) on SA Chip can bind Human BAFFR, Fc Tag (Cat. No. BAR-H5257) with an affinity constant of 26.7 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Customer Reviews

Synonym Name

BAFFR,TNFRSF13C,BROMIX,CD268,CVID4,prolixin,BAFF-R

Background

BAFF receptor (B-cell activating factor receptor, BAFF-R), also known as tumor necrosis factor receptor superfamily member 13C (TNFRSF13C), is a membrane protein of the TNF receptor superfamily which recognizes BAFF. B-cell activating factor (BAFF) enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Ianalumab NOV-5; VAY-736 Phase 3 Clinical Morphosys Ag, Novartis Pharma Ag Anemia, Hemolytic, Autoimmune; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Thrombocytopenia; Hepatitis, Autoimmune; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Purpura, Thrombocytopenic, Idiopathic; Lupus Erythematosus, Systemic; Multiple Sclerosis; Lupus Nephritis; Idiopathic Pulmonary Fibrosis; Arthritis, Rheumatoid; Sjogren's Syndrome; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone Details
CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd, Zhejiang University Lymphoma, B-Cell; Autoimmune Diseases Details
ESG-206 ESG-206 Phase 1 Clinical Shanghai Escugen Biotechnology Co Ltd Lymphoma, B-Cell; Neoplasms; Lymphoma Details
AUR-200 AUR-200; AUR200 Phase 1 Clinical Thunderbolt Pharma Inc Autoimmune Diseases Details
BAFFR-CAR T cell therapy (PeproMene Bio Inc) PMB-CT01; PMB-101 Phase 1 Clinical PeproMene Bio Inc, City Of Hope National Medical Center Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute Details
Ianalumab NOV-5; VAY-736 Phase 3 Clinical Morphosys Ag, Novartis Pharma Ag Anemia, Hemolytic, Autoimmune; Pemphigus; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Thrombocytopenia; Hepatitis, Autoimmune; Primary mediastinal B cell lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Purpura, Thrombocytopenic, Idiopathic; Lupus Erythematosus, Systemic; Multiple Sclerosis; Lupus Nephritis; Idiopathic Pulmonary Fibrosis; Arthritis, Rheumatoid; Sjogren's Syndrome; Hematologic Neoplasms; Lymphoma, B-Cell, Marginal Zone Details
CD19-BAFF Targeted CAR T-cells Therapy(YaKe Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd, Zhejiang University Lymphoma, B-Cell; Autoimmune Diseases Details
ESG-206 ESG-206 Phase 1 Clinical Shanghai Escugen Biotechnology Co Ltd Lymphoma, B-Cell; Neoplasms; Lymphoma Details
AUR-200 AUR-200; AUR200 Phase 1 Clinical Thunderbolt Pharma Inc Autoimmune Diseases Details
BAFFR-CAR T cell therapy (PeproMene Bio Inc) PMB-CT01; PMB-101 Phase 1 Clinical PeproMene Bio Inc, City Of Hope National Medical Center Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute Details

This web search service is supported by Google Inc.

totop

Laisser un message